India, June 8 -- Lupin Limited has announced a strategic collaboration with Spain-based LABORATORIOS ERN S.A. (ERN) for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed-dose combination therapy delivered through a pressurized metered-dose inhaler (pMDI), in Spain.
The medication is indicated for the treatment of adult patients suffering from asthma and chronic obstructive pulmonary disease (COPD).
The partnership combines Lupin's expertise in respiratory care and inhalation technology with ERN's strong commercial presence and established relationships within the Spanish healthcare market. The launch marks another step in Lupin's strategy to expand access to advanced respiratory treatments across international markets....